Zymeworks Inc.: Truist Securities raises target price to $36 from $35
ZYME•Truist Securities raised its target price for Zymeworks to $36 from $35.
Related News
F5 survey finds security tops AI model deployment challenges at 48%
FFIV•
CVS Health Corporation: Argus Research cuts target price to $105 from $114
CVS•
Viavi Solutions target price cut to $52 from $66 by Argus Research
VIAV•
Zoetis participates in Jefferies Global Healthcare Conference
ZTS•
Olema Pharmaceuticals names Jason O'Byrne chief financial officer
OLMA•